New York to probe Mylan EpiPen contracts for schools
- Wall St. touches two-week high on deals, strong earnings
- Unusual 11 Mid-Day Movers 10/24: (UNIS) (MBVT) (ACCO) Higher; (TDW) (INO) (BCC) Lower
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) to Acquire B/E Aerospace (BEAV) for $6.4B
- TD Ameritrade (AMTD) to Acquire Scottrade in $4B Cash & Stock Deal
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
WASHINGTON (Reuters) - New York has opened a probe into whether Mylan Pharmaceuticals (NASDAQ: MYL) broke antitrust law in writing contracts to provide EpiPens to some schools systems, state Attorney General Eric Schneiderman said in a statement on Tuesday.
A person briefed on the matter said the New York attorney general's office has subpoenaed documents from Mylan over the EpiPen program.
There had been allegations that schools which had used Mylan's EpiPen4Schools program, which gives many schools the devices for free, were contractually barred from buying products from Mylan competitors for a year. Senators Richard Blumenthal and Amy Klobuchar asked the Federal Trade Commission on Tuesday to investigate the allegation.
Mylan did not immediately respond to a request for comment.
(Reporting by Diane Bartz and David Shepardson; Editing by David Gregorio)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- White pushes bigger SEC role in regulating U.S. Treasuries
- Basic Energy Services (BAS) to File for Chapter 11 Bankruptcy; Enters RSA with Certain Lenders, Noteholders
- Negative tone of White House race sours young voters
Create E-mail Alert Related CategoriesGeneral News, Litigation, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!